In its latest annual review of the biotech industry, business consulting firm Ernst & Young finds a sector in flux (for 2003 stats see Nat. Biotechnol. 22, 789, 2004). Profitability still looks distant; although revenues for public companies were up by 17%, so were net losses. Employment was up in the US and in Asia, but plummeted (down 21%) in Europe; the number of private companies contracted significantly in both the US and Europe, whereas Asia showed strong growth.
Credit: Source: Ernst & Young
Credit: Source: Ernst & Young
Credit: Source: Ernst & Young
Credit: Source: Ernst & Young
Credit: Source: Ernst & Young
Credit: Source: Ernst & Young
Rights and permissions
About this article
Cite this article
Lawrence, S. State of biotech sector—2004. Nat Biotechnol 23, 774 (2005). https://doi.org/10.1038/nbt0705-774
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0705-774
